3,3-dimethyl-2-oxo-1H-indol-5-ylboronic acid | 304876-33-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3,3-dimethyl-2-oxo-1H-indol-5-ylboronic acid
• 英文别名: (2'-oxo-[2,3-dihydro-3,3-dimethyl-1,3'-[3H]indol]-5'-yl)boronic acid；(3,3-Dimethyl-2-oxoindolin-5-YL)boronic acid；(3,3-dimethyl-2-oxo-1H-indol-5-yl)boronic acid
• CAS: 304876-33-3
• 化学式: C₁₀H₁₂BNO₃
• 分子量: 205.021
• InChiKey: PWAZSJIPGMUMQY-UHFFFAOYSA-N

物化性质

• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-溴-5-氟苯腈 、 3,3-dimethyl-2-oxo-1H-indol-5-ylboronic acid 生成 3-(3,3-Dimethyl-2oxo-2,3-dihydro-1H-indol-5-yl)5-fluoro-benzonitrile
  参考文献：
  名称：

  Cyclic regimens utilizing indoline derivatives

  摘要：

  这项发明涉及利用替代吲哚啉衍生物化合物的循环组合疗法和方案，这些化合物是孕激素受体拮抗剂，具有以下一般结构： 其中R1和R2可以是单一取代基或融合形成螺环，结合孕激素、雌激素或两者。这些治疗方法可用于避孕或用于治疗和/或预防继发性闭经、功能性出血、子宫平滑肌瘤、子宫内膜异位症、多囊卵巢综合征、子宫内膜、卵巢、乳腺、结肠、前列腺的癌症和腺癌，或减少副作用或周期性月经出血。该发明的其他用途包括促进食物摄入。

  公开号：

  US06462032B1
• 作为产物：
  描述：

  1,2-二氢-3,3-二甲基-2-氧代-3H-吲哚 在 溴 、 sodium acetate 、 sodium hydride 、 溶剂黄146 作用下， 以 四氢呋喃 为溶剂， 生成 3,3-dimethyl-2-oxo-1H-indol-5-ylboronic acid
  参考文献：
  名称：

  New progesterone receptor antagonists: 3,3-disubstituted-5-aryloxindoles

  摘要：

  A neck series of 3,3-disubstituted-5-aryloxindoles has been synthesized and evaluated for progesterone receptor antagonist (PR) activity in a T47D cell alkaline phosphatase assay and for their ability to bind PR in competition binding studies. In this communication, the synthesis and structurc-activiy relationships (SARs) of various 3,3-substituents are discussed where it is clear that small alkyl and spiroalkyl groups are required to achieve better PR antagonist activity. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00746-1

文献信息

• Cyclic regimens utilizing indoline derivatives
  申请人：Wyeth

  公开号：US06462032B1

  公开（公告）日：2002-10-08

  This invention relates to cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor having the general structure: wherein R1 and R2 may be single substituents or fused to form spirocyclic rings, in combination with progestins, estrogens, or both. These methods of treatment may be used for contraception or for the treatment and/or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or minimization of side effects or cyclic menstrual bleeding. Additional uses of the invention include stimulation of food intake.

  这项发明涉及利用替代吲哚啉衍生物化合物的循环组合疗法和方案，这些化合物是孕激素受体拮抗剂，具有以下一般结构： 其中R1和R2可以是单一取代基或融合形成螺环，结合孕激素、雌激素或两者。这些治疗方法可用于避孕或用于治疗和/或预防继发性闭经、功能性出血、子宫平滑肌瘤、子宫内膜异位症、多囊卵巢综合征、子宫内膜、卵巢、乳腺、结肠、前列腺的癌症和腺癌，或减少副作用或周期性月经出血。该发明的其他用途包括促进食物摄入。
• Thio-oxindole derivatives
  申请人：American Home Products Corporation

  公开号：US06355648B1

  公开（公告）日：2002-03-12

  This invention relates to compounds which are agonists of the progesterone receptor which have the general structures: wherein: R1 and R2 are H, alkyl, substituted alkyl; OH; O(alkyl); O(substituted alkyl); OAc; aryl; substituted aryl; heteroaryl; substituted heteroaryl; alkylaryl; alkylheteroaryl; 1-propynyl; or 3-propynyl; or R1 and R2 are joined to form an alkyl, alkenyl or heterocyclic ring; or R1 and R2 together comprise a double bond to CMe2; C(cycloalkyl), O, or C(cycloether); R3 is H, OH, NH2, C1 to C6 alkyl, substituted C1 to C6 alkyl, C3 to C6 alkenyl, alkynyl, substituted alkynyl, or CORA; RA is H, C1 to C3 alkyl, substituted C1 to C3 alkyl, C1 to C3 alkoxy, substituted C1 to C3 alkoxy, C1 to C3 aminoalkyl, or substituted C1 to C3 aminoalkyl; R4 is H, halogen, CN, NH2, NO2, C1 to C6 alkyl, or substituted C1 to C6 alkyl, C1 to C6 alkoxy, substituted C1 to C6 alkoxy, C1 to C6 aminoalkyl, or substituted C1 to C6 aminoalkyl; R5 is optionally substituted and selected from a benzene ring, a five or six membered heterocyclic ring with 1, 2, or 3 heteroatoms selected from O, S, SO, SO2 or NR6; or an indol-4-yl, indol-7-yl or benzo-2-thiophene moiety; Q1 is S, NR7, CR8R9; or a pharmaceutically acceptable salt thereof, as well as methods of using these compounds to induce contraception or treat progesterone-related carcinomas and adenocarcinomas.

  这项发明涉及激素受体的激动剂化合物，其具有以下一般结构： 其中： R1和R2为H、烷基、取代烷基；OH；O(烷基)；O(取代烷基)；OAc；芳基；取代芳基；杂环芳基；取代杂环芳基；烷基芳基；烷基杂环芳基；1-丙炔基；或3-丙炔基；或R1和R2连接形成烷基、烯基或杂环环；或R1和R2共同包括与CMe2形成双键的C(环烷基)、O或C(环醚)；R3为H、OH、NH2、C1至C6烷基、取代C1至C6烷基、C3至C6烯基、炔基、取代炔基，或CORA；RA为H、C1至C3烷基、取代C1至C3烷基、C1至C3烷氧基、取代C1至C3烷氧基、C1至C3氨基烷基，或取代C1至C3氨基烷基；R4为H、卤素、CN、NH2、NO2、C1至C6烷基，或取代C1至C6烷基、C1至C6烷氧基，取代C1至C6烷氧基、C1至C6氨基烷基，或取代C1至C6氨基烷基；R5为可选择取代并选自苯环、具有1、2或3个来自O、S、SO、SO2或NR6的杂原子的五元或六元杂环环；或吲哚-4-基、吲哚-7-基或苯并-2-噻吩基团；Q1为S、NR7、CR8R9；或其药学上可接受的盐，以及使用这些化合物诱导避孕或治疗与孕激素相关的癌症和腺癌的方法。
• [EN] MODULATORS OF THR-β AND METHODS OF USE THEREOF<br/>[FR] MODULATEURS DE THR-β ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ALIGOS THERAPEUTICS INC

  公开号：WO2020227549A8

  公开（公告）日：2021-05-27
• New progesterone receptor antagonists: 3,3-disubstituted-5-aryloxindoles
  作者：Andrew Fensome、Reinhold Bender、Jeffrey Cohen、Mark A. Collins、Valerie A. Mackner、Lori L. Miller、John W. Ullrich、Richard Winneker、Jay Wrobel、Puwen Zhang、Zhiming Zhang、Yuan Zhu

  DOI：10.1016/s0960-894x(02)00746-1

  日期：2002.12

  A neck series of 3,3-disubstituted-5-aryloxindoles has been synthesized and evaluated for progesterone receptor antagonist (PR) activity in a T47D cell alkaline phosphatase assay and for their ability to bind PR in competition binding studies. In this communication, the synthesis and structurc-activiy relationships (SARs) of various 3,3-substituents are discussed where it is clear that small alkyl and spiroalkyl groups are required to achieve better PR antagonist activity. (C) 2002 Elsevier Science Ltd. All rights reserved.